Cargando…

Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy

Lytic bone metastases are rare in prostate cancer. We here present 18 fluorine fluorodeoxyglucose ((18)F-FDG) positron emission tomography computed tomography (PET-CT) images of a 67-year-old male patient with lytic metastases from prostate cancer. Repeat (18)F-FDG PET-CT done 6 months later showed...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Punit, Karunanithi, Sellam, Singh Dhull, Varun, Jain, Sachin, Bal, Chandrasekhar, Kumar, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822421/
https://www.ncbi.nlm.nih.gov/pubmed/24250030
http://dx.doi.org/10.4103/0972-3919.119545
_version_ 1782290411756191744
author Sharma, Punit
Karunanithi, Sellam
Singh Dhull, Varun
Jain, Sachin
Bal, Chandrasekhar
Kumar, Rakesh
author_facet Sharma, Punit
Karunanithi, Sellam
Singh Dhull, Varun
Jain, Sachin
Bal, Chandrasekhar
Kumar, Rakesh
author_sort Sharma, Punit
collection PubMed
description Lytic bone metastases are rare in prostate cancer. We here present 18 fluorine fluorodeoxyglucose ((18)F-FDG) positron emission tomography computed tomography (PET-CT) images of a 67-year-old male patient with lytic metastases from prostate cancer. Repeat (18)F-FDG PET-CT done 6 months later showed response to medical castration therapy. While the role of (18)F-FDG PET-CT for sclerotic bone metastases in prostate cancer remains controversial, it appears to be useful for detection and response assessment of lytic prostate cancer metastases.
format Online
Article
Text
id pubmed-3822421
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38224212013-11-18 Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy Sharma, Punit Karunanithi, Sellam Singh Dhull, Varun Jain, Sachin Bal, Chandrasekhar Kumar, Rakesh Indian J Nucl Med Case Report Lytic bone metastases are rare in prostate cancer. We here present 18 fluorine fluorodeoxyglucose ((18)F-FDG) positron emission tomography computed tomography (PET-CT) images of a 67-year-old male patient with lytic metastases from prostate cancer. Repeat (18)F-FDG PET-CT done 6 months later showed response to medical castration therapy. While the role of (18)F-FDG PET-CT for sclerotic bone metastases in prostate cancer remains controversial, it appears to be useful for detection and response assessment of lytic prostate cancer metastases. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3822421/ /pubmed/24250030 http://dx.doi.org/10.4103/0972-3919.119545 Text en Copyright: © Indian Journal of Nuclear Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Sharma, Punit
Karunanithi, Sellam
Singh Dhull, Varun
Jain, Sachin
Bal, Chandrasekhar
Kumar, Rakesh
Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy
title Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy
title_full Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy
title_fullStr Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy
title_full_unstemmed Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy
title_short Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy
title_sort prostate cancer with lytic bone metastases: 18f-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822421/
https://www.ncbi.nlm.nih.gov/pubmed/24250030
http://dx.doi.org/10.4103/0972-3919.119545
work_keys_str_mv AT sharmapunit prostatecancerwithlyticbonemetastases18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfordiagnosisandmonitoringresponsetomedicalcastrationtherapy
AT karunanithisellam prostatecancerwithlyticbonemetastases18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfordiagnosisandmonitoringresponsetomedicalcastrationtherapy
AT singhdhullvarun prostatecancerwithlyticbonemetastases18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfordiagnosisandmonitoringresponsetomedicalcastrationtherapy
AT jainsachin prostatecancerwithlyticbonemetastases18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfordiagnosisandmonitoringresponsetomedicalcastrationtherapy
AT balchandrasekhar prostatecancerwithlyticbonemetastases18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfordiagnosisandmonitoringresponsetomedicalcastrationtherapy
AT kumarrakesh prostatecancerwithlyticbonemetastases18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfordiagnosisandmonitoringresponsetomedicalcastrationtherapy